Ardelyx, Inc. (ARDX) is a publicly traded Healthcare sector company. As of May 21, 2026, ARDX trades at $6.26 with a market cap of $1.51B and a P/E ratio of -24.10. ARDX moved +2.79% today. Year to date, ARDX is +2.96%; over the trailing twelve months it is +50.00%. Its 52-week range spans $3.21 to $8.40. Analyst consensus is strong buy with an average price target of $16.60. Rallies surfaces ARDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Ardelyx Q1 Revenue Up 38% to $93.4M; IBSRELA Sales Reach $70.1M: Ardelyx posted $93.4M in Q1 revenue, up 38% year-over-year, driven by 58% growth in IBSRELA sales to $70.1M and $23.3M from XPHOZAH. The company holds $238.1M in cash and reiterated 2026 guidance of $410M-$430M for IBSRELA and $110M-$120M for XPHOZAH while advancing Phase 3 CIC and pediatric trials.
| Metric | Value |
|---|---|
| Price | $6.26 |
| Market Cap | $1.51B |
| P/E Ratio | -24.10 |
| EPS | $-0.26 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.40 |
| 52-Week Low | $3.21 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $407.32M |
| Net Income | $-61.60M |
| Gross Margin | 90.29% |
5 analysts cover ARDX: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $16.60.